CUTISS Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $69.7M

  • Investors
  • 12

CUTISS General Information

Description

Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin grafts use patients' cells in combination with a hydrogel to create dermo-epidermal skin and considerably reduce the need for autografting and further corrective interventions, allowing for considerable savings, enabling patients to get treated for affected or damaged skin.

Contact Information

Website
www.cutiss.swiss
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • CUTISS Haus, Grabenstrasse 11
  • 8952 Schlieren
  • Switzerland
+41 044
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • CUTISS Haus, Grabenstrasse 11
  • 8952 Schlieren
  • Switzerland
+41 044

CUTISS Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CUTISS Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Later Stage VC (Series C) 10-Sep-2025 $69.7M Completed Clinical Trials - Phase 3
13. Grant 02-May-2023 Completed Clinical Trials - Phase 3
12. Later Stage VC 10-Feb-2023 Completed Clinical Trials - Phase 3
11. Later Stage VC 17-Jun-2022 Completed Clinical Trials - Phase 3
10. Accelerator/Incubator 28-Feb-2022 Completed Clinical Trials - Phase 1
9. Grant 25-Jan-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC 16-Dec-2020 Completed Clinical Trials - Phase 2
7. Later Stage VC (Series B) 29-Jun-2020 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series A) 27-Jun-2018 $10.9M $12M Completed Clinical Trials - Phase 1
5. Grant 01-Jan-2018 $4.05M $1.04M Completed Clinical Trials - Phase 1
To view CUTISS’s complete valuation and funding history, request access »

CUTISS Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference
Ordinary
Ordinary
Ordinary
Series B
Series B
Series A 390,600 $0.124447 $31.11 $31.11 1x $31.11 10.38%
Series A 53,496 $0.124447 $24.89 $24.89 1x $24.89 1.42%
To view CUTISS’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

CUTISS Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of customized bio-engineered skin grafts designed to treat large skin defects. The company's customized skin g
Biotechnology
Schlieren, Switzerland
50 As of 2026

Burlington, MA
 

Dublin, Ireland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

CUTISS Competitors (2)

One of CUTISS’s 2 competitors is Vericel, a Formerly PE-Backed company based in Burlington, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vericel Formerly PE-Backed Burlington, MA
Mallinckrodt Pharmaceuticals Formerly PE-Backed Dublin, Ireland
You’re viewing 2 of 2 competitors. Get the full list »

CUTISS Patents

  • 60

    Total Documents Applications and Grants

  • Total Patents Families

  • 26

    Granted

  • 26

    Pending

  • Expiring in next 12 mo

CUTISS Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024296539-A1 Use of hair stem cells in wound healing Pending 09-Jul-2023
EP-4739325-A1 Use of hair stem cells in wound healing Pending 09-Jul-2023
US-20260263528-A1 Use of hair stem cells in wound healing Pending 09-Jul-2023
WO-2025012893-A1 Use of hair stem cells in wound healing Inactive 09-Jul-2023
AU-2022296956-A1 Tissue culture vessel for preparation of compressed hydrogel skin grafts and related methods and systems Pending 20-Jun-2021 C12M21/08
To view CUTISS’s complete patent history, request access »

CUTISS Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CUTISS Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cherry Bay Capital Group Family Office Minority
Lichtsteiner Foundation Limited Partner Minority
GG 1978 Venture Capital Minority
Government of Francaise Government
GISEV Family Office Family Office Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

CUTISS FAQs

  • When was CUTISS founded?

    CUTISS was founded in 2015.

  • Where is CUTISS headquartered?

    CUTISS is headquartered in Schlieren, Switzerland.

  • What is the size of CUTISS?

    CUTISS has 50 total employees.

  • What industry is CUTISS in?

    CUTISS’s primary industry is Biotechnology.

  • Is CUTISS a private or public company?

    CUTISS is a Private company.

  • What is the current valuation of CUTISS?

    The current valuation of CUTISS is .

  • What is CUTISS’s current revenue?

    The current revenue for CUTISS is .

  • How much funding has CUTISS raised over time?

    CUTISS has raised $139M.

  • Who are CUTISS’s investors?

    Cherry Bay Capital Group, Lichtsteiner Foundation, GG 1978, Government of Francaise, and GISEV Family Office are 5 of 12 investors who have invested in CUTISS.

  • Who are CUTISS’s competitors?

    Vericel and Mallinckrodt Pharmaceuticals are competitors of CUTISS.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process